|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Burkitt Lymphoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins.
|
27424208 |
2016 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In our study, GNA13 was reported to be significantly up-regulated in HCC tissues, and this was correlated with several clinicopathological parameters, including tumor multiplicity (P = 0.004), TNM stage (P = 0.002), and BCLC stage (P = 0.010).
|
27883022 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Gα12 and Gα13, encoded by GNA12 and GNA13, respectively, are referred to as the GEP oncogene and are implicated in tumor progression.
|
26804165 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Overall, we show that Gα13 and DDR1-Par3 differentially regulate cell-cell junctions and the actin cytoskeleton to mediate invasion in three-dimensional collagen.
|
26589794 |
2016 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our study demonstrates GNA13 may be served as a prognostic biomarker for HCC patients after curative hepatectomy, in which high expression of GNA13 suggests poor prognosis of HCC patients.
|
27883022 |
2016 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, re-expression of GNA13 (without the 3'-UTR) could partially abrogate the miR-30b-5p-induced cell proliferation and metastasis inhibition.
|
28536082 |
2017 |
|
Schizophrenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The protein profile indicates attenuation of "GNA13-ERK signaling" in schizophrenia brain.
|
28214564 |
2017 |
|
Bone Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Collectively, we reveal that Gα13 is a master endogenous negative switch for osteoclastogenesis through regulation of the RhoA/Akt/GSK3β/NFATc1 signalling pathway, and that manipulating Gα13 activity might be a therapeutic strategy for bone diseases.
|
28102206 |
2017 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit α-13 in renal cell carcinoma.
|
28536082 |
2017 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consequently, Gα13 ablation in muscles enhanced whole-body energy metabolism and increased insulin sensitivity, thus affording protection from diet-induced obesity and hepatic steatosis.
|
28920922 |
2017 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results define Gα13 as a switch regulator of myofiber reprogramming, implying that modulations of Gα13 and its downstream effectors in skeletal muscle are a potential therapeutic approach to treating metabolic diseases.
|
28920922 |
2017 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consequently, Gα13 ablation in muscles enhanced whole-body energy metabolism and increased insulin sensitivity, thus affording protection from diet-induced obesity and hepatic steatosis.
|
28920922 |
2017 |
|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Notably, Gα13 gain-of-function inhibits Akt activation and osteoclastogenesis, and protects mice from pathological bone loss in disease models.
|
28102206 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit α-13 in renal cell carcinoma.
|
28536082 |
2017 |
|
Hyperactive behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Gna13-deficiency triggers a drastic increase in both osteoclast number and activity (hyper-activation), mechanistically through decreased RhoA activity and enhanced Akt/GSK3β/NFATc1 signalling.
|
28102206 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we demonstrate that GNA13 is upregulated in many solid tumors and impacts survival and metastases in patients.
|
29255247 |
2018 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
GNA13 has been found overexpressed in various types of cancer, which is related to tumor metastasis and progression.
|
30267476 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
This study aimed to explore the role of GNA13 in CRC and investigate the mechanism of how GNA13 promotes tumor growth.
|
30267476 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers.
|
29255247 |
2018 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, these data indicate that GNA13 expression is a potential prognostic biomarker for tumor progression, and that interfering with GNA13-induced signaling provides a novel strategy to block TICs and drug resistance in HNSCCs.
|
29255247 |
2018 |